EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

   

From 9 to 17 June,  the European Hematology Association’s annual congress (EHA 2021 Virtual), will be held. This is one of the most important haematology congresses in Europe.

Find below a selection of the most relevant abstracts and presentations on myeloma and AL amyloidosis at EHA 2021:

  • Developing treatment attributes for a patient preference survey: a qualitative multinational study in multiple myeloma. Read this abstract here. This research is part of the IMI-PREFER project developed KU Leuven in collaboration with Myeloma Patients Europe (MPE). This poster will be released on Friday 11 at 9.00 CET.  
  • Depth of response and MRD status in ultra high-risk myeloma and plasma cell leukaemia treated with Dara-CVRdand augmented autologous transplant: results of the risk-stratified UK optimum/MUKnine trial. Read this abstract here.
  • Efficacy of carfilzomib-based induction/consolidation with or without autologous transplant and lenalidomide or carfilzomib-lenalidomide maintenance in high-risk patients in the FORTE trial. Read this abstract here.
  • Updated results from phase 3 ANDROMEDA study of patients with newly diagnosed light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone plus subcutaneous daratumumab. Read this abstract here.
  • Daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma treated with bortezomib, thalidomide, and dexamethasone ± daratumumab and ASCT: CASSIOPEIA part 2 results. Read this abstract here.
  • Teclistamab, a b-cell maturation antigen (BCMA) × cd3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: updated phase 1 results. Read the abstract here.
  • Talquetamab, a g protein-coupled receptor family c group 5 member d (GPRC5D) × cd3 bispecific antibody, in relapsed/refractory multiple myeloma: updated results of phase 1, first-in-human study. Read the abstract here.
  • Updates from ICARIA-MM, a phase 3 study of isatuximab (ISA) plus pomalidomide and low-dose dexamethasone (PD) versus PD in relapsed and refractory multiple myeloma (RRMM). Read this abstract here.
  • EHA-Patient Joint Symposium. Keep an eye out for the EHA-Patient Joint  Symposium happening on Wednesday 9, Friday 11 and Saturday 12.






Recent news

» EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myeloma

» EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myeloma

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.